Passage Bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7492
- Today's High:
- $0.7987
- Open Price:
- $0.75
- 52W Low:
- $0.714
- 52W High:
- $1.92
- Prev. Close:
- $0.76
- Volume:
- 85551
Company Statistics
- Market Cap.:
- $42.42 million
- Book Value:
- 2.748
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -24.88%
- Return on Equity TTM:
- -56.2%
Company Profile
Passage Bio Inc had its IPO on 2020-02-28 under the ticker symbol PASG.
The company operates in the Healthcare sector and Biotechnology industry. Passage Bio Inc has a staff strength of 85 employees.
Stock update
Shares of Passage Bio Inc opened at $0.75 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.75 - $0.8, and closed at $0.76.
This is a +0.13% increase from the previous day's closing price.
A total volume of 85,551 shares were traded at the close of the day’s session.
In the last one week, shares of Passage Bio Inc have slipped by -1.68%.
Passage Bio Inc's Key Ratios
Passage Bio Inc has a market cap of $42.42 million, indicating a price to book ratio of 0.3039 and a price to sales ratio of 0.
In the last 12-months Passage Bio Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-94310000. The EBITDA ratio measures Passage Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Passage Bio Inc’s operating margin was 0% while its return on assets stood at -24.88% with a return of equity of -56.2%.
In Q2, Passage Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Passage Bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Passage Bio Inc’s profitability.
Passage Bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.7685. Its price to sales ratio in the trailing 12-months stood at 0.
Passage Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $193.70 million
- Total Liabilities
- $19.87 million
- Operating Cash Flow
- $13.97 million
- Capital Expenditure
- $103000
- Dividend Payout Ratio
- 0%
Passage Bio Inc ended 2024 with $193.70 million in total assets and $0 in total liabilities. Its intangible assets were valued at $193.70 million while shareholder equity stood at $150.41 million.
Passage Bio Inc ended 2024 with $0 in deferred long-term liabilities, $19.87 million in other current liabilities, 5000.00 in common stock, $-550600000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $30.29 million and cash and short-term investments were $151.48 million. The company’s total short-term debt was $3,326,000 while long-term debt stood at $0.
Passage Bio Inc’s total current assets stands at $153.63 million while long-term investments were $0 and short-term investments were $121.19 million. Its net receivables were $433000.00 compared to accounts payable of $3.38 million and inventory worth $0.
In 2024, Passage Bio Inc's operating cash flow was $13.97 million while its capital expenditure stood at $103000.
Comparatively, Passage Bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.76
- 52-Week High
- $1.92
- 52-Week Low
- $0.714
- Analyst Target Price
- $6.67
Passage Bio Inc stock is currently trading at $0.76 per share. It touched a 52-week high of $1.92 and a 52-week low of $1.92. Analysts tracking the stock have a 12-month average target price of $6.67.
Its 50-day moving average was $0.85 and 200-day moving average was $1.1 The short ratio stood at 1.14 indicating a short percent outstanding of 0%.
Around 896.1% of the company’s stock are held by insiders while 6591.5% are held by institutions.
Frequently Asked Questions About Passage Bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.